Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00237263
Status:
COMPLETED
Last Update Posted:
2024-01-11
First Post:
2005-10-07
Brief Title:
An Extension Study of Entacapone in Patients With Parkinsons Disease With End-of-dose Wearing-off This Study is Not Recruiting in the United States
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinsons Disease With End-of-dose Wearing-off
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinsons disease with end-of-dose wearing-off
This study is not recruiting patients in the United States
This study is not recruiting patients in the United States
Detailed Description:
The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinsons disease with end-of-dose wearing-off
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None